In the early 1950's, the Company's founders discovered that cartilage powder significantly hastened the healing of surgical wounds in animals. Early clinical studies by the Company, supported by extensive product testing and refinement, led to the creation of a proprietary process for purifying bovine cartilage to produce a sterile white powder that could be used to optimize healing. The resulting product was given the brand name Catrix. The Company believes there is persuasive evidence that Catrix functions in the body as a biological response modifier, regulating the components of the immune system. Some observed effects of Catrix on the body include:
Company profile
Ticker
LCAR
Exchange
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
SEC CIK
Corporate docs
IRS number
132538207
Latest filings (excl ownership)
REVOKED
Registration or securities revoked
9 Mar 23
NT 10-K
Notice of late annual filing
29 Aug 17
10-Q
2017 Q3
Quarterly report
12 Apr 17
10-Q
2017 Q2
Quarterly report
12 Jan 17
10-Q
2017 Q1
Quarterly report
18 Oct 16
10-K
2016 FY
Annual report
30 Sep 16
8-K
Changes in Registrant's Certifying Accountant
29 Aug 16
NT 10-K
Notice of late annual filing
29 Aug 16
10-Q
2016 Q3
Quarterly report
14 Apr 16
10-Q
2016 Q2
Quarterly report
13 Jan 16
Latest ownership filings